Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6H 3V4, Canada; email:
BC Children's Hospital Research Institute, Vancouver, British Columbia V5Z 4H4, Canada.
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:65-84. doi: 10.1146/annurev-pharmtox-030920-025745. Epub 2020 Oct 2.
The clinical implementation of pharmacogenetic biomarkers continues to grow as new genetic variants associated with drug outcomes are discovered and validated. The number of drug labels that contain pharmacogenetic information also continues to expand. Published, peer-reviewed clinical practice guidelines have also been developed to support the implementation of pharmacogenetic tests. Incorporating pharmacogenetic information into health care benefits patients as well as clinicians by improving drug safety and reducing empiricism in drug selection. Barriers to the implementation of pharmacogenetic testing remain. This review explores current pharmacogenetic implementation initiatives with a focus on the challenges of pharmacogenetic implementation and potential opportunities to overcome these challenges.
随着与药物疗效相关的新遗传变异体的不断发现和验证，药物遗传生物标志物的临床应用也在不断发展。包含药物遗传信息的药物标签数量也在不断增加。此外，还制定了已发表的同行评议临床实践指南，以支持药物遗传检测的实施。将药物遗传信息纳入医疗保健中，通过提高药物安全性和减少药物选择中的经验主义，使患者和临床医生都受益。然而，药物遗传检测的实施仍然存在障碍。本文综述了当前的药物遗传实施计划，重点探讨了药物遗传实施所面临的挑战以及克服这些挑战的潜在机会。
